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ABSTRACT
Background/Aims: To evaluate the retinal toxicity of
Brilliant Blue G (BBG) following intravitreal injection in rat
eyes and examine the biocompatibility and the staining
properties in humans.
Methods: BBG was injected into the 11 rat eyes to
evaluate toxic effects with balanced salt solution (BSS)
serving as control. Retinal toxicity was assessed by retinal
ganglion cell (RGC) counts and by light microscopy 7 days
later. In addition, BBG was applied during vitrectomy for
macular hole (MH) (n = 15) or epiretinal membranes
(ERM) (n = 3) in a prospective, non-comparative con-
secutive series of patients. Before and after surgery, all
patients underwent a complete clinical examination
including measurement of best corrected visual acuity
(VA) and intraocular pressure, perimetry, fundus photo-
graphy and optical coherence tomography. Patients were
seen 1 day before surgery and then in approximately four
weeks intervals.
Results: No significant reduction in RGC numbers and no
morphological alterations were noted. A sufficient staining
of the internal limiting membrane (ILM) was seen in
patients with MH, while the staining pattern in ERM cases
was patchy, indicating that parts of the ILM were peeled
off along with the ERM in a variable extent. All MHs could
be closed successfully. VA improved in 10 eyes (56%; 8/
15 MH patients, 2/3 ERM patients), was unchanged in
four eyes (22%; all MH patients) and was reduced in four
eyes (22%; 3/15 MH, 1/3 ERM). No toxic effects
attributable to the dye were noted during patient follow-
up. The ultrastructure of tissue harvested during surgery
was unremarkable.
Conclusion: Brilliant Blue provides a sufficient and
selective staining of the ILM. No retinal toxicity or adverse
effects related to the dye were observed in animal and
human studies. The long-term safety of this novel dye will
have to be evaluated in larger patient series and a longer
follow-up.
Vital dyes have become very popular to visualise
barely visible structures such as the internal limit-
ing membrane (ILM) during macular hole (MH)
surgery using Indocyanine Green (ICG),1 epiretinal
membranes (ERM) using Trypan Blue (TB)2 and
the vitreous, which can be visualised using
Bromophenol Blue.3 The main advantages of ICG
were the good contrast provided and its selective
staining properties. However, at present the ‘‘off
label’’ intravitreal application of ICG has become a
subject of ongoing discussion, as toxic effects of the
dye leading to functional impairment of the
patients cannot be ruled out.4–7 TB appears to be
safe for intraocular application, but provides a far
less pronounced staining of the ILM and lacks the
selective staining properties of ICG and requires a
fluid–air exchange to achieve high enough concen-
tration on the retinal surface. The latter may be
overcome by special TB preparations.8 Recently,
Enaida and co-workers introduced Brilliant Blue G
(BBG) as an alternative for ILM peeling.9–11 The
purpose of this investigation was to assess poten-
tial retinal toxicity of BBG in a well-established12
animal model and to evaluate the staining proper-
ties and safety profile in a prospective series of
patients undergoing MH and ERM surgery.
MATERIALS AND METHODS
Animal study
Animals
All experiments were performed in accordance
with guidelines for animal care in the European
Community and those of the Association for
Research in Vision and Ophthalmology. Male
Brown Norway rats (Charles River, Sulzfeld,
Germany) with a body weight of 120–160 g were
used. Rats were housed under a 12 h light–dark
cycle.
Intravitreal dye injections
Eleven adult male Brown Norway rats were
anaesthetised with an intraperitoneal injection of
chloral hydrate (7%, 6 ml/kg body weight).
Intravitreal BBG (Brilliant Peel; Fluoron GmbH,
Neu-Ulm, Germany/306 mOsm/kg H2O;
pH = 7.52) injections were performed using a
heat-pulled glass capillary connected to a micro-
syringe (Drummond Scientific, Broomall, PA),
under direct observation through the microscope.
Eyes with lens damage were excluded from the
experiments and not used thereafter. Single injec-
tions of 2 ml of BBG (0.25%) were performed,
reaching a final intraocular BBG concentration of
0.025% (estimated for an average rat eye intravi-
treal volume of 20 ml). Contralateral eyes served as
control eyes and were injected with balanced salt
solution (BSS).
Retrograde labelling and quantification of retinal
ganglion cells (RGC)
RGC survival was assessed as described previously.12
In brief, anaestetised rats were placed into a
stereotaxic frame (TSE systems, Bad Homburg,
Germany). A portion of the skull and the meninges
were removed, exposing the neocortex overlying the
tectum on the side contralateral of the lesioned eye.
Three injections of the fluorescent tracer Fluorogold
(Hydroxystilbamidine methanesulfonate, Molecular
Probes, Eugene, OR) were made over a period of
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2 min each targeting all layers of both superior colliculi. Two days
later, the animals were sacrificed with a choral hydrate overdose.
Eyes were enucleated, retinas dissected, flat-mounted, and fixed in
3% paraformaldehyde (PFA) for 30 min. Visualisation was
performed immediately under fluorescent microscope. Before
enucleation the cornea was marked at the 12 o’clock position for
orientation in retinal quadrants. The RGC-counting was carried
out in 12 distinct areas of 62 500 mm2. Images obtained using a
digital imaging system (ImagePro 3.0, Media Cybernetics, Silver
Spring, MD) connected to a microscope were coded and analysed
in a masked fashion. Labelled cells were defined as surviving.
Counts are expressed as the cell density (cells per square
millimetre).
Statistical analysis was performed using a Student t test.
Differences were considered significant when p,0.05.
Histology
After sacrifice, the eyes of three animals were immediately
immersion-fixed in Ito’s solution (2.5% glutaraldehyde, 2.5%
paraformaldehyde, 10.1% picric acid in 0.1 M cacodylate buffer,
pH 7.2). The eyes were bisected into nasal and temporal
segments, and the specimens postfixed in 1% osmium tetroxide,
rinsed in cacodylate buffer, dehydrated in an ascending series of
alcohols and embedded in araldite. Semithin sections were cut
along a superior–inferior plane, stained with Toluidine Blue and
investigated by light microscopy.
The total thickness of the neural retina and the thickness of
the different retinal layers were quantitatively evaluated in the
central retina. The measuring field was defined by a distance of
200 mm from the optic nerve head rim, and the single-thickness
measurements were obtained within the next 300 mm periph-
erally. Since there was no statistic difference between the
superior and inferior region, the data were pooled for statistical
analysis using the Wilcoxon test (p = 0.01).
Clinical investigation in humans
Dye application and surgery
The study was approved by the local Institutional review board
(IRB) and ethics committee. In a prospective, interventional,
non-comparative clinical case series, eyes from consecutive
patients with a MH, 13 idiopathic, one myopic and one
traumatic MH (n = 15) or epiretinal membranes (ERM, n = 3)
were included between April and September 2007. Macular
holes were clinically classified according to Gass.13 Concomitant
retinal diseases, such as very mild non-proliferative diabetic
retinopathy in one patient or mild changes attributed to age-
related macular degeneration as seen in three patients, were
accepted if the visual acuity (VA) of the non-study eye was not
affected. All patients underwent standard 20-gauge three-port
pars plana vitrectomy as described earlier.6 BBG solution
(0.5 mL, 0.25%, Brilliant Peel; Fluoron GmbH, Neu-Ulm,
Germany) was injected into the fluid filled globe over the
macular area and washed out after a few seconds by irrigation.
In patients with ERM, the dye was injected following the
removal of the visible part of the ERM. The stained ILM was
then grabbed using an end-gripping forceps and peeled off. A
15% hexafluoroethane (C2F6) gas mixture was used as a
tamponade in MH cases, and patients were encouraged to keep
a prone position for 5 days. Tissue removed during surgery was
prepared for ultrastructural anaylsis as described previously.14
All surgeries were performed by a single surgeon (CH), who also
graded the staining of the ILM during surgery as good, weak,
variable or absent.
Clinical examination
Before and after surgery, all patients underwent a complete
clinical examination including measurement of best corrected
VA and intraocular pressure (IOP), colour and red-free fundus
photography and optical coherence tomography (OCT) (Stratus
OCT, Carl Zeiss Meditec, Jena, Germany). With respect to our
previous observations6 of peripheral visual field defects, we
preferred manual Goldmann perimetry for the assessment of the
visual field before and after surgery. However, if during follow-
up a complete Goldmann perimetry could not be obtained, we
performed an automated perimetry for the 30u visual field,
completed by an evaluation of the periphery by manual
Goldmann perimetry.
Multifocal electroretinography (MERG) was performed in
randomly selected cases (n = 14). Patients were seen 1 day
before surgery and then in approximately 4-week intervals by
one of the authors (MR). While the clinical examination, fundus
photography and OCT were performed at each follow-up visit,
perimetry and MERG were performed at the first postoperative
examination.
Exclusion criteria were ocular diseases such as glaucoma,
ischaemic optic neuropathy, any intraocular surgery within the
last 60 days of the study eye, age less than 18 years and
participation in other clinical investigations.
The treated eye, adverse events as well as the patient’s lens
status (phakic or pseudophakic), gender, age and treated eye
were recorded. OCT was used to support the clinical diagnosis
of a MH and evaluate the anatomic configuration of the
macular area postoperatively and to measure retinal thickness
(mm) in patients with ERMs.
Statistical analysis of pre- and postoperative VA was
performed using a two-tailed Wilcoxon signed ranks test for
two related samples. Differences were considered significant
when p,0.05. Patients’ characteristics are summarised in
table 1.
RESULTS
Animal study
RGC numbers
Whole mounts with Fluorogold-labelled retinal ganglion cells
were photographed 7 days after injections of BBG and injections
of balanced salt solution as controls (fig 1). Retinal ganglion
cells numbers were then counted (fig 2); numbers are expressed
as cell densities. In BBG injected eyes (2129 (61) cells/mm2,
mean (SEM), n = 11) no statistically significant differences in
RGC densities were observed compared with BSS injected eyes
(2202 (85), n = 5, p = 0.43).
Histological evaluation
BBG- and BSS-injected eyes showed normal retinal morphology
with no signs of inflammation or degeneration throughout the
central and peripheral retina. Quantification of the central
retinal layers revealed normal values in the BBG-treated eyes
and no statistical differences (table 2).
Clinical investigation in humans
We included 13 women and five men with a mean age of
67 years (SD 10) years in this investigation. We treated 10 right
and eight left eyes. The mean follow-up up was 8 (3) weeks
(range 4–14 weeks).
Over all patients, the mean VA before surgery was 20/80 (20/
200) SD (range from 20/400 to 20/40) and increased not
significantly to 20/60 (20/100) SD (range from 20/250 to 20/25)
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after surgery (p = 0,094). Looking at the group of MH patients,
the mean VA improved not significantly (p = 0,090) from 20/
100 (20/200) SD (range from 20/400 to 20/40) to 20/60 (20/
100) SD (range from 20/250 to 20/25). VA improved in 10 eyes
(56%, 8/15 MH patients, 2/3 ERM patients), was unchanged
in four eyes (22%, all MH patients) and decreased in four eyes
(28%, 3/15 MH, 1/3 ERM). In MH patients, the lack of visual
improvement was partially related to the pathogenesis of the
MH such as myopic and traumatic MH (patient 5 and 6) or
may be attributed to concomitant diseases such as diabetic
retinopathy and age-related macular degeneration (ARMD)
(patients 10 and 11) that might have had an influence on the
development of visual acuity. Two of the ERM patients
(patients 16 and 17) developed a macular oedema seen shortly
after surgery with an increase in retinal thickness to 412 mm
and 630 mm respectively and a visual acuity of 20/40 and 20/
500. They were therefore treated by retrobulbar steroid
injection, which led to a significant improvement of both
retinal thickness (327 mm and 378 mm) and visual acuity
(20/30 each) (table 1). The IOP was in normal range at any
time.
In five eyes, surgery had been performed as a combined
procedure of vitrectomy and cataract extraction with posterior
chamber lens implantation. Nine eyes were pseudophakic at the
last follow-up visit.
All MHs were completely closed as shown by optic coherence
tomography or clinical investigation after the first surgical
intervention. In one patient (patient 6) with a large traumatic
MH, the rim of the was postoperatively attached but still
visible.
Table 1 Clinical data of all patients
Case no.
Age
(years) Sex Eye Diagnosis
Follow-up
(weeks)
VA Lens status
ERM: retinal
thickness in OCT
(mm) MH in
OCT
(Post)
Visual-
field
defect
Adverse
events
ILM
stainingPre Post Pre Post Pre Post
1 70 F R MH Stage 3 5 20/100 20/100 Phakic Phakic Closed None None Weak
2 75 F R MH Stage 4 5 20/400 20/200 Phakic Phakic Closed None None Good
3 66 F R MH Stage 2 7 20/50 20/30 Pseudo-
phakic
Pseudo-
phakic
Closed None None Good
4 79 M L MH Stage 2 5 20/40 20/80 Phakic Phakic Closed None None Good
5 41 F R MH Stage 4 High
Myopia
6 20/60 20/100 Phakic Phakic Closed None None Good
6 46 M L Traumatic MH 6 20/200 20/200 Phakic Phakic Closed
rim still
visible
None None Good
7 68 F R MH Stage 2 7 20/60 20/50 Pseudo-
phakic
Pseudo-
phakic
Closed None None Good
8 67 F R MH Stage 3 12 20/100 20/50 Phakic Phakic Closed None None Good
9 62 F L MH Stage 4 14 20/60 20/60 Phakic Phakic Closed None None Good
10 74 F R MH Stage 3 ARMD 9 20/100 20/100 Phakic Pseudo-
phakic
Closed None None Good
11 76 F L MH Stage 3 DR,
ARMD
10 20/200 20/200 Pseudo-
phakic
Pseudo-
phakic
Closed None None Good
12 77 M L MH Stage 2 6 20/60 20/25 Phakic Pseudo-
phakic
Closed None None Good
13 72 F R MH Stage 4 ARMD 8 20/100 20/60 Phakic Phakic Closed None None Good
14 71 F L MH Stage 4 8 20/200 20/250 Phakic Pseudo-
phakic
Closed None None Good
15 65 F R MH Stage 3 4 20/200 20/40 Phakic Pseudo-
phakic
Closed None None Good
16 72 M R ERM 14 20/50 20/30 Pseudo-
phakic
Pseudo-
phakic
360 327 None None Variable
17 63 F L ERM 12 20/50 20/30 Phakic Pseudo-
phakic
336 378 None None Variable
18 73 M L ERM 8 20/50 20/100 Phakic Phakic 331 360 None None Variable
ARMD, age-related macular degeneration; DR diabetic retinopathy; ERM, epiretinal membrane; F, female; L, left; M, male; ME, macular oedema; MH, macular hole; Post,
postoperative; Pre, preoperative; R, right; VA, visual acuity.
Figure 1 Fluorogold-labelled retinal
ganglion cells photographed 7 days after
injections of Brilliant Blue G (A) and
injections of balanced salt solution (B) as
controls.
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We did not observe any visual field defects or any
abnormalities in the other functional tests such as MERG that
might indicate toxic effects of the dye. Fundus photographs did
not show any abnormal alterations of the retinal pigment
epithelium or defects of the nerve fibre layer seen in red-free
images. There were no systemic side effects.
Staining of the ILM during MH surgery was successful in 15
cases and allowed for an easy and controlled removal of the ILM
with no haemorrhages of the retinal surface indicating surgical
trauma (fig 3). In patients with ERMs, the staining of the ILM
was variable. This was most likely attributed to the fact that
the dyes had been injected after removal of the ERM, indicating
that the ILM is peeled off along with the ERM in a variable
extent. Transmission electron microscopy confirmed the pre-
sence of the ILM in all processed specimens (n = 18). The
complete data on our patients are presented in table 1.
Ultrastructure of removed membranes
The ultrastructural analysis revealed fragments of the ILM in all
specimens. There was a variable amount of epiretinal cellular
proliferation seen at the vitreal side of the ILM without any cellular
damage. The nuclei and cytoplasmatic elements such as mitochon-
driae or golgi complexes were well preserved. At the retinal side of
the ILM, no relevant amount of retinal debris was seen (fig 4)
DISCUSSION
There is common agreement that toxic effects of any new dye
suggested to assist intraocular surgery need to be carefully ruled
out prior to its routine use in humans. Shortly after ICG had
been recommended for ILM peeling,3 a less favourable func-
tional outcome and a high incidence of peripheral visual field
defects6 15 16 led to a still ongoing discussion on potential toxic
effects of ICG which may be related to its photosensitising
properties.17 18 The safety margin of ICG is unclear, and some
authors did not observe any dye-related complications.19 20 A
new and promising dye to visualise the ILM may be BBG.10 11
First, experimental and clinical data, obtained in animals and
humans, addressed the toxicity of BBG following subretinal
injection9 and revealed a good biocompatibility of BBG in
contrast to control dyes including ICG and TB. An experimental
study exposing glial cells to ICG and BBG disclosed ICG toxicity
as seen by the induction of apoptosis, involving induction of the
caspase cascade through p38 mitogen-activated protein kinase
phosphorylation while BBG did not cause apoptosis and
therefore could be considered a safer adjuvant.21 In our own
study, the dye was injected intravitreally and therefore had
contact to the retinal surface but not the subretinal space as in
previous investigations.9 The analysis of retinal ganglion cell
numbers showed that intravitreal BBG did not lead to a
significant change in RGC numbers in rat retina in vivo. It is
important to note that our experimental setting to assess retinal
toxicity does not resemble the situation in vitreoretina surgery
exactly. First, the dye is injected into the vitreous gel, which is
usually removed in human eyes before applying the dye during
vitreoretinal surgery, which could lead to a higher local dose of
the dye during vitreoretinal surgery. Second, the exposure time
of 7 days in the rat eye is much longer than the intended
application in humans, where the dye is washed out immedi-
ately by irrigation. However, we chose this setting, as it seems
reasonable to assume that a dye leading to no visible toxic effect
after 1 week will not show such an effect after 1 minute as well.
Although the extended exposure time as chosen here offers
additional information on the safety margin of BBG, one has to
keep in mind that toxicity studies in animals may not resemble
all possible toxic effects in a clinical situation in humans.
Therefore, long-term side effects seen in humans during
prospective clinical trials cannot be ruled out.
Following the positive results of our investigation in the
animal, we decided to use the dye in humans as well. BBG was
applied to assist MH surgery and surgery for epiretinal
membranes. In MH surgery, the dye provided a excellent
contrast of the ILM and allowed for a complete removal of the
ILM. We did not observe any functional deficits in terms of
visual field defects in our patient as seen following the use of
ICG.6 No abnormalities of the RPE were seen clinically and in
fundus photographs, although the dye may very well have come
into contact with the RPE through the MH. The closure rate
was comparable with our results obtained without dye
assistance.22 VA improvement in MH patients was less
pronounced compared with our previous studies where we
observed a mean VA of 20/40 postoperatively.22 From our point
of view, this is related to the relatively short follow-up in some
patients, patient selection including concomitant diseases such
as high myopia, trauma, ARMD or DR and the lens status.
Despite the relatively short follow-up in some cases, conclusions
on the safety of BBG can be drawn as in previous investigations
on ICG adverse events such as visual field defects becoming
apparent already at the first follow-up visit.6 Of note, we did
not observe any defects of the nerve fibre layer seen in red-free
Figure 2 Retinal ganglion cell (RGC) numbers counted and numbers
expressed as cell densities. In Brilliant Blue G-injected eyes (2129 (61)
cells/mm2, mean (SEM), n = 11) no statistically significant differences in
retinal ganglion cell densities were observed compared with balanced
salt solution (BSS)-injected eyes (2202 (85), n = 5, p = 0.43).
Table 2 Quantification of the central retinal layers
Total (mm) NFL (mm) GCL (mm) IPL (mm) INL (rows) OPL (mm) ONL (rows) PR-IS (mm) PR-OS (mm)
OD, mean (SD) 223 (7) 8.5 (2.9) 12.6 (2.4) 67 (7) 5.2 (0.4) 6.4 (0.9) 9.8 (0.4) 17 (3) 26 (3)
OS, mean (SD) 216 (8) 8.9 (1.4) 13.2 (2.5) 64 (4) 5.2 (0.4) 7.5 (0.9) 9.8 (0.4) 15 (3) 24 (2)
Quantification of the central retina in Brilliant Blue G (OS) and BSS (OD, control) injected eyes.
GCL, ganglion-cell layer; INL, inner nuclear layer; IPL, inner plexiform layer; NFL, nerve-fibre layer; ONL, outer nuclear layer; OPL, outer plexiform layer; PR-IS, photo receptor inner
segment; PR-OS, photoreceptor outer segment; Total, whole thickness.
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fundus photographs as described in previous publications on
ILM peeling without any dye.23 These asymptomatic defects
had been additionally confirmed by microperimetry as central
visual field defects and were very likely correlated to a
mechanical, focal trauma of the innermost retinal layers by
ILM peeling. One may conclude therefore that BBG-assisted
ILM peeling is less traumatic to the nerve fibre layer.
During surgery for epiretinal membranes BBG was injected
following the removal of the visible epiretinal membrane using an
end-gripping forceps in order to visualise fragments of the ILM
which were not removed along with the epiretinal membrane. As
a consequence, the staining pattern was not as homogenous as
seen during MH surgery, but provided a more patchy aspect. As
during MH surgery, the ILM could be easily removed without
damage to the underlying retina and with no toxic effects of the
dye seen postoperatively. However, during all surgical procedures,
the surgeon noted an increased rigidity of the stained ILM
compared with previous surgeries without BBG application.
Our data underline the good biocompatibility of BBG and its
applicability and safety for the use in humans. BBG provides a
sufficient and selective staining of the ILM. No retinal toxicity
related to BBG was observed in our animal study and our short-
term clinical investigation in humans. As mentioned earlier, we
feel that it is of great importance to collect as much safety data
as possible on a new dye suggested for intraocular surgery in
humans. The long-term safety of this novel dye will have to be
evaluated in larger patient series and a longer follow-up.
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